AR105160A1 - Métodos de modulación de moléculas de vigilancia de adn citosólicas - Google Patents
Métodos de modulación de moléculas de vigilancia de adn citosólicasInfo
- Publication number
- AR105160A1 AR105160A1 ARP160101937A ARP160101937A AR105160A1 AR 105160 A1 AR105160 A1 AR 105160A1 AR P160101937 A ARP160101937 A AR P160101937A AR P160101937 A ARP160101937 A AR P160101937A AR 105160 A1 AR105160 A1 AR 105160A1
- Authority
- AR
- Argentina
- Prior art keywords
- subject
- immunomodulatory composition
- administering
- nucleic acid
- acid sequence
- Prior art date
Links
- 230000001086 cytosolic effect Effects 0.000 title 1
- 230000002519 immonomodulatory effect Effects 0.000 abstract 7
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 4
- 230000037451 immune surveillance Effects 0.000 abstract 4
- 150000007523 nucleic acids Chemical group 0.000 abstract 4
- 230000028993 immune response Effects 0.000 abstract 3
- 230000003308 immunostimulating effect Effects 0.000 abstract 3
- 230000019491 signal transduction Effects 0.000 abstract 3
- 241000283690 Bos taurus Species 0.000 abstract 2
- 125000002091 cationic group Chemical group 0.000 abstract 2
- 230000015788 innate immune response Effects 0.000 abstract 2
- 239000002502 liposome Substances 0.000 abstract 2
- 239000003981 vehicle Substances 0.000 abstract 2
- 230000004584 weight gain Effects 0.000 abstract 2
- 235000019786 weight gain Nutrition 0.000 abstract 2
- 101710196623 Stimulator of interferon genes protein Proteins 0.000 abstract 1
- 239000004599 antimicrobial Substances 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
- 208000023504 respiratory system disease Diseases 0.000 abstract 1
- 230000004936 stimulating effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/17—Immunomodulatory nucleic acids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Dispersion Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562185230P | 2015-06-26 | 2015-06-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR105160A1 true AR105160A1 (es) | 2017-09-13 |
Family
ID=56235815
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP160101937A AR105160A1 (es) | 2015-06-26 | 2016-06-28 | Métodos de modulación de moléculas de vigilancia de adn citosólicas |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20190233825A1 (enExample) |
| EP (1) | EP3313376A2 (enExample) |
| JP (1) | JP2018518511A (enExample) |
| KR (1) | KR20180021874A (enExample) |
| CN (1) | CN108472255A (enExample) |
| AR (1) | AR105160A1 (enExample) |
| AU (1) | AU2016282879A1 (enExample) |
| BR (1) | BR112017028121A2 (enExample) |
| CA (1) | CA2990526A1 (enExample) |
| CL (1) | CL2017003373A1 (enExample) |
| CR (1) | CR20180003A (enExample) |
| DO (1) | DOP2017000313A (enExample) |
| HK (1) | HK1256128A1 (enExample) |
| IL (1) | IL256264A (enExample) |
| MX (1) | MX2017017141A (enExample) |
| PE (1) | PE20181208A1 (enExample) |
| PH (1) | PH12017502413A1 (enExample) |
| RU (1) | RU2018102915A (enExample) |
| SG (1) | SG10201913395VA (enExample) |
| TW (1) | TW201710509A (enExample) |
| UY (1) | UY36756A (enExample) |
| WO (1) | WO2016207314A2 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2015349680A1 (en) | 2014-11-21 | 2017-06-08 | Northwestern University | The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates |
| NZ750181A (en) | 2016-07-26 | 2023-02-24 | Bayer Animal Health Gmbh | Increased fertility in bovine species |
| US11364304B2 (en) | 2016-08-25 | 2022-06-21 | Northwestern University | Crosslinked micellar spherical nucleic acids |
| WO2018209270A1 (en) | 2017-05-11 | 2018-11-15 | Northwestern University | Adoptive cell therapy using spherical nucleic acids (snas) |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US155950A (en) * | 1874-10-13 | Improvement in hand-saws | ||
| EP1167378B1 (en) * | 1994-07-15 | 2011-05-11 | University of Iowa Research Foundation | Immunomodulatory oligonucleotides |
| US6339068B1 (en) * | 1997-05-20 | 2002-01-15 | University Of Iowa Research Foundation | Vectors and methods for immunization or therapeutic protocols |
| US6693086B1 (en) * | 1998-06-25 | 2004-02-17 | National Jewish Medical And Research Center | Systemic immune activation method using nucleic acid-lipid complexes |
| EP1326969B1 (en) * | 2000-09-25 | 2009-04-15 | Genetronics, Inc. | Improved system for regulation of transgene expression |
| AU2002953015A0 (en) * | 2002-12-02 | 2002-12-12 | Women's And Children's Hospital | Modified lacz gene |
| WO2005033265A2 (en) * | 2003-04-25 | 2005-04-14 | Epimmune Inc. | Optimized multi-epitope constructs and uses thereof |
| PE20050386A1 (es) * | 2003-05-29 | 2005-06-23 | Schering Plough Ltd | Composiciones farmaceuticas de florfenicol |
| DK1789559T3 (en) * | 2004-08-13 | 2015-08-24 | Univ Pennsylvania | Methods to construct vaccines with no antibiotic resistance |
| JP2008511545A (ja) * | 2004-08-13 | 2008-04-17 | ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア | 抗生物質耐性欠失ｄｎａワクチン |
| PT2992899T (pt) * | 2009-05-14 | 2020-09-21 | Bayer Ip Gmbh | Resposta imunitária reforçada em espécies aviárias |
| UY33821A (es) * | 2010-12-22 | 2012-07-31 | Bayer Animal Health Gmbh | Respuesta inmune potenciada en la especie bovina |
| CA2834442A1 (en) * | 2011-05-26 | 2012-11-29 | Intervet International B.V. | Immunostimulatory oligodeoxynucleotides |
| AR091569A1 (es) * | 2012-06-28 | 2015-02-11 | Intervet Int Bv | Receptores de tipo toll |
| BR112016019837A2 (pt) * | 2014-02-28 | 2017-10-17 | Bayer Animal Health Gmbh | plasmídeos imunoestimuladores |
-
2016
- 2016-06-23 SG SG10201913395VA patent/SG10201913395VA/en unknown
- 2016-06-23 MX MX2017017141A patent/MX2017017141A/es unknown
- 2016-06-23 RU RU2018102915A patent/RU2018102915A/ru not_active Application Discontinuation
- 2016-06-23 PE PE2017002822A patent/PE20181208A1/es unknown
- 2016-06-23 EP EP16732278.3A patent/EP3313376A2/en not_active Withdrawn
- 2016-06-23 US US15/738,794 patent/US20190233825A1/en not_active Abandoned
- 2016-06-23 CA CA2990526A patent/CA2990526A1/en not_active Abandoned
- 2016-06-23 CN CN201680049705.XA patent/CN108472255A/zh active Pending
- 2016-06-23 AU AU2016282879A patent/AU2016282879A1/en not_active Abandoned
- 2016-06-23 JP JP2017566839A patent/JP2018518511A/ja active Pending
- 2016-06-23 HK HK18115209.5A patent/HK1256128A1/zh unknown
- 2016-06-23 WO PCT/EP2016/064613 patent/WO2016207314A2/en not_active Ceased
- 2016-06-23 CR CR20180003A patent/CR20180003A/es unknown
- 2016-06-23 BR BR112017028121A patent/BR112017028121A2/pt not_active IP Right Cessation
- 2016-06-23 KR KR1020187002687A patent/KR20180021874A/ko not_active Withdrawn
- 2016-06-24 TW TW105120099A patent/TW201710509A/zh unknown
- 2016-06-27 UY UY0001036756A patent/UY36756A/es not_active Application Discontinuation
- 2016-06-28 AR ARP160101937A patent/AR105160A1/es not_active Application Discontinuation
-
2017
- 2017-12-12 IL IL256264A patent/IL256264A/en unknown
- 2017-12-22 PH PH12017502413A patent/PH12017502413A1/en unknown
- 2017-12-26 DO DO2017000313A patent/DOP2017000313A/es unknown
- 2017-12-26 CL CL2017003373A patent/CL2017003373A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3313376A2 (en) | 2018-05-02 |
| BR112017028121A2 (pt) | 2018-09-04 |
| CR20180003A (es) | 2018-03-20 |
| DOP2017000313A (es) | 2018-02-28 |
| CA2990526A1 (en) | 2016-12-29 |
| IL256264A (en) | 2018-02-28 |
| CN108472255A (zh) | 2018-08-31 |
| PH12017502413A1 (en) | 2018-06-25 |
| AU2016282879A1 (en) | 2018-01-18 |
| RU2018102915A3 (enExample) | 2019-12-05 |
| WO2016207314A3 (en) | 2017-02-09 |
| WO2016207314A2 (en) | 2016-12-29 |
| RU2018102915A (ru) | 2019-07-29 |
| HK1256128A1 (zh) | 2019-09-13 |
| MX2017017141A (es) | 2018-03-09 |
| US20190233825A1 (en) | 2019-08-01 |
| UY36756A (es) | 2017-01-31 |
| JP2018518511A (ja) | 2018-07-12 |
| CL2017003373A1 (es) | 2018-06-29 |
| KR20180021874A (ko) | 2018-03-05 |
| PE20181208A1 (es) | 2018-07-23 |
| TW201710509A (zh) | 2017-03-16 |
| SG10201913395VA (en) | 2020-03-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112019008369A2 (pt) | ácidos ribonucleicos mensageiros para intensificar respostas imunes e métodos para uso dos mesmos | |
| ECSP17064523A (es) | Composiciones y métodos para activar la señalización dependiente del "estimulador del gen de interferon" | |
| PE20191152A1 (es) | Anticuerpos y polipeptidos dirigidos contra cd127 | |
| MX2023001319A (es) | Polipeptidos condicionalmente activos. | |
| CL2020001181A1 (es) | Nuevos receptores de células t modificados genéticamente y terapias inmunológicas que emplean los mismos. | |
| PE20191648A1 (es) | Nuevos receptores de celulas t y terapia inmunologica que los utiliza | |
| PE20191081A1 (es) | Nuevos receptores de celulas t y terapia inmunologica que los utiliza | |
| MX2022005955A (es) | Metodos y composiciones para terapia celular adoptiva. | |
| PE20190335A1 (es) | Receptores de celulas t | |
| CY1121535T1 (el) | Πρωτεϊνικα κατασκευασματα uspa2 και χρησεις αυτων | |
| AR105160A1 (es) | Métodos de modulación de moléculas de vigilancia de adn citosólicas | |
| BR112017014219A2 (pt) | vacinas à base de nanopartículas multivalentes | |
| BR112018006006A2 (pt) | receptores de antígeno, cadeias peptídicas, células recombinantes, métodos para produzir uma célula que expressa um receptor de antígeno e para o tratamento de uma doença, ácidos nucleicos e composição farmacêutica | |
| CR20170419A (es) | Nuevos péptidos y nueva combinación de péptidos para el uso en la inmunoterapia contra el cáncer de páncreas y otros tipos de cáncer. | |
| CO6460752A2 (es) | Respuesta inmunitaria reforzada en especies aviares | |
| EA201791381A1 (ru) | Универсальная клетка т-киллер | |
| AR080313A1 (es) | Composiciones de virus de moquillo canino (cdv) recombinante y sus usos | |
| PE20200933A1 (es) | Composiciones inmunoestimulantes | |
| BR112016011866A2 (pt) | vetores de composições e métodos para induzir uma resposta imune potencializada usando vetores de poxvírus | |
| BR112017028552A2 (pt) | partículas e conjugados direcionados e formulações dos mesmos | |
| ES2721159T3 (es) | Antígenos asociados a tumor independientes de MHC novedosos | |
| CL2020002561A1 (es) | Composiciones y métodos para el tratamiento de la distrofia macular | |
| CO2017001614A2 (es) | Vacuna en vector recombinante de adenovirus aviar serotipo 9 | |
| UY36990A (es) | Derivados de anticuerpos contra el vih con actividad dual antiviral e inmunomodulatoria | |
| ECSP22064620A (es) | COMPOSICIÓN INMUNOGÉNICA VIVA RECOMBINANTE QUE COMPRENDE EL VIRUS DE LA ENFERMEDAD DE NEWCASTLE (NDV) QUE EXPRESA LA SUBUNIDAD S1 Y EL RBD DE LA PROTEINA SPIKE DEL SARS-CoV-2 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |